Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Padua variant factor IX gene shines in AMT-061

Publish date:: March 6, 2019

Key clinical point: AMT-061, a novel gene therapy, provides clinically meaningful factor XI activity in hemophilia B.

Major finding: Mean factor IX activity level was 38% of normal 12 weeks after gene therapy.

Study details: An ongoing, phase 2b study involving three patients with moderate to severe or severe hemophilia B.

Disclosures: The investigators reported financial relationships with Bayer, UniQure, Pfizer, Novo Nordisk, Shire, and others.

Citation:

Von Drygalski A et al. EAHAD 2019, Abstract OR10.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Bleeding Disorders

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

Hemochromatosis variants may confer 10-fold higher risk of liver cancer,

Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk,